$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Since the discovery of penicillin in 1928, natural products derived from environmental microorganisms have proven to be a rich source of antimicrobial compounds1. Approximately 80% of natural product antibiotics are derived from bacteria of the genus Streptomyces and other actinomycetes, while the remaining 20% is produced by fungal species1. Some of the most common antibiotic scaffolds used in the clinic such as the β-lactams, tetracyclines, rifamycins, and aminoglycosides, were originally isolated from microbes2. However, due to the rise of multidrug resistant (MDR) bacteria, our current panel of antibiotics has become less effective in treatment3,4. These include the “ESKAPE” pathogens (i.e., vancomycin-resistant enterococci and β-lactam-resistant Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacter sp.), which are a subset of bacteria deemed to be associated with the highest risk by a number of major public health authorities such as the World Health Organization3,4,5. The emergence and global spread of these MDR pathogens results in a constant need for novel antibiotics3,4,5. Regrettably, the past two decades have demonstrated that the discovery of novel antibiotics from microbial sources is increasingly difficult6. Current approaches to drug discovery include the high-throughput screening of bioactive compounds, including natural product extract libraries, allowing for thousands of extracts to be tested at a given time2. However, once antimicrobial activity is detected, the next step is to analyze the contents of the crude extract to identify the active component and eliminate those containing known or redundant compounds7,8. This process, referred to as dereplication, is vital to prevent and/or significantly reduce the time spent on the re-discovery of known antibiotics7,9. Although a necessary step in natural product drug discovery, dereplication is notoriously laborious and resource-intensive10.
Ever since Beutler et al. first coined the term “dereplication”, extensive efforts have been made to develop innovative strategies for the rapid identification of known antibiotics11,12. Today the most common tools used for dereplication include analytical chromatographic systems such as high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance-based detection methods11,13. Unfortunately, each of these methods requires the use of expensive analytical equipment and sophisticated data interpretation.
In an attempt to develop a dereplication method that can be rapidly performed without specialized equipment, we established the antibiotic resistance platform (ARP)10. The ARP can be used for the discovery of antibiotic adjuvants, the profiling of new antibiotic compounds against known resistance mechanisms, and the dereplication of known antibiotics in extracts derived from actinobacteria and other microbes. Here, we focus on its application in antibiotic dereplication. The ARP utilizes a library of isogenic Escherichia coli strains expressing individual resistance genes that are effective against the most commonly re-discovered antibiotics14,15. When the E. coli library is grown in the presence of a secondary metabolite-producing organism, the identity of the compound can be deduced by the growth of E. coli strains that express its associated resistance gene10. When the ARP was first reported, the library consisted of >40 genes conferring resistance to 16 antibiotic classes. The original dereplication template was designed to encompass a subset of resistance genes per antibiotic class to provide information regarding antibiotic subclass during the dereplication process. Today, the ARP is comprised of >90 genes that confer resistance to 18 antibiotic classes. Using our extensive collection of resistance genes, a secondary dereplication template has been developed and is known as the minimal antibiotic resistance platform (MARP). This template was created to eliminate gene redundancy and to simply provide information regarding the general antibiotic class that a dereplicated metabolite is related to. Additionally, the MARP template possesses both wildtype and a hyperpermeable/efflux deficient strain of E. coli BW25113 (E. coli BW25113 ΔbamBΔtolC), compared to the original incarnation of the ARP, which only utilizes the hyperpermeable strain. This unique aspect creates additional phenotypes during dereplication, indicating a compounds ability to cross the outer membrane of Gram-negative bacteria. Here, we describe a robust protocol to be followed when dereplicating with either the ARP and/or MARP, highlight the most critical steps to be followed, and discuss the various possible outcomes.